Target intelligence / Profile preview

Sarcoplasmic/endoplasmic reticulum calcium ATPase (PfATP6) (PfATP6)

Target
PfATP6
Molecular classification
Transporter, Enzyme
01

Overview

Sarcoplasmic/endoplasmic reticulum calcium ATPase (PfATP6) is a P-type Ca2+-transporting ATPase encoded by the malaria parasite Plasmodium falciparum. It is the parasite's ortholog of the mammalian sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and plays an essential role in maintaining intracellular calcium homeostasis by pumping calcium ions from the cytosol into the endoplasmic reticulum. PfATP6 is a validated therapeutic target, historically proposed as a primary target of the artemisinin class of antimalarial drugs (including artemisinin, artesunate, artemether, and dihydroartemisinin), which inhibit its calcium-pumping activity and disrupt calcium signaling, leading to parasite death. Although some controversy exists regarding whether artemisinins act solely or primarily through PfATP6, genetic studies and functional assays in heterologous expression systems (such as yeast and Xenopus oocytes) support its interaction with these drugs. Mutations in the pfatp6 gene, such as L263E, S769N, and A623E, have been associated with reduced susceptibility to artemisinins in vitro and in field isolates, making them important markers for monitoring drug resistance. Additionally, PfATP6 is inhibited by other SERCA inhibitors like thapsigargin and cyclopiazonic acid, though with a distinct pharmacological profile compared to mammalian SERCA.

Other names
PfSERCAPfATPase6Sarcoplasmic/endoplasmic reticulum Ca2+-ATPaseP-type Ca(2+) transporterCalcium-transporting ATPaseCa2+-transporting ATPaseATP6
02

Mechanism of action

Inhibition of calcium transport and ATPase activity, leading to disruption of intracellular calcium homeostasis and parasite cell death

03

Biological functions

Calcium ion transportCalcium homeostasisATP hydrolysis
04

Disease associations

Infection
05

Safety considerations

Emergence of drug resistancePotential off-target inhibition of mammalian SERCA orthologs (e.g., SERCA3 in neutrophils)
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

pfatp6 gene mutations (e.g., L263E, S769N, A623E)

Beyond the preview

Go deeper on Sarcoplasmic/endoplasmic reticulum calcium ATPase (PfATP6) (PfATP6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sarcoplasmic/endoplasmic reticulum calcium ATPase (PfATP6) (PfATP6).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call